CNS
-
AbbVie boasts that it will become the largest CNS company in the industry next year!
In the field of biopharmaceuticals, there is no eternal No. 1, only infinite possibilities
-
艾伯维放出豪言：明年将成为业内最大的CNS公司！
全文共1900字，共1图 预计阅读时间：7分钟 新官上任三把火！ 2025年7月31日，在艾伯维第二季度财报电话会议上，现任总裁兼首席执行官（CEO）Robert A. Micha…
-
An asset similar to Roche’s trontinemab | DrugTimes BD Project
If interested in this asset, please feel free to contact the BD team at DrugTimes immediately! Please send an email to BD@drugtimes.cn
-
CNS赛道火热升温！罗氏trontinemab数据积极！感兴趣类似产品？请速速联系 | 药时代BD项目DTC-082
如果贵公司对该项目感兴趣，欢迎立即联系药时代BD团队！请发送邮件到BD@drugtimes.cn
-
Global market opportunity! Buyers in urgent need of CNS-related products/platforms.
On July 9, 2025, Novartis struck another deal, acquiring Sironax’s “Brain Deli…
-
被安慰剂“做了局”？又一款CNS药物倒下了
全文共2800字 预计阅读时间：7分钟 近期，Relmada Therapeutics向美国证券交易委员会（SEC）提交的文件中宣布已停止其在研NMDA 受体拮抗剂艾司美沙酮（es…
-
马斯克重磅宣布Neuralink最新计划；中国抗体药物接连出海；Summit PD-1/VEGF双抗三期临床OS积极，但股价大跌30%；Biogen进军CNS研发；罗氏与Orionis Biosciences达成第二笔交易
每日发布，持续更新。欢迎广大朋友们关注，一起学习进步！
-
【IND enabling】Once daily oral brain-penetrant dual JAK1/TYK2 inhibitor with better efficacy and safety
For any questions, please contact DrugTimes BD Team at BD@drugtimes.cn, please include Project ID in the subject. Many thanks!
-
The “Black Monday” for CNS drug-developing companies. Is the placebo “going wild and uncontrollable”?
To explore more efficient and stable clinical trial protocols, these “failures” are inevitably part of the cost
-
siRNA Therapeutics Targeting APP for Alzheimer’s Disease (AD) 【Product for Licensing】
If you are interested in this asset or need more information, please kindly contact DrugTimes BD Team at BD@drugtimes.cn, we will present the non-confidential deck to you for review asap. Many thanks!~
